President and Chief Executive Officer
Steven Lo is our Chief Executive Officer and member of the board of directors. Steve was previously the chief commercial officer at Puma Biotechnology where he built the commercial operations infrastructure and team to launch the company’s first product, NERLYNX®, in the United States while leading the execution of global licensing agreements for rest of world. Previously, he was senior vice president and chief commercial officer at Corcept Therapeutics. At Corcept, Mr. Lo formed the commercial organization to launch the company’s first product, Korlym®, an endocrine specialty medication for a rare orphan disease (Cushing’s syndrome) and also was responsible for the corporate strategy and development of the company’s oncology franchise. Earlier in his career, he spent 13 years at Genentech in increasingly responsible roles in market access, sales and marketing, ultimately serving as franchise head, Endocrinology. He started his career in the pharmaceutical industry at AstraZeneca after holding roles in finance and operations at Kaiser Permanente. Mr. Lo holds a master’s in health administration from the University of Southern California and a B.S. in microbiology from the University of California, Davis.
Chief Financial Officer
Greg Kitchener is the Chief Financial Officer of Zosano, where he oversees Accounting, Financial Planning and Analysis, Tax, Treasury, Investor Relations, Information Technology and Facilities. Mr. Kitchener has over 20 years of broad financial leadership experience in financial planning and analysis, treasury, accounting and investor relations. Prior to joining Zosano, he served as the CFO of BioPharmX, a public, specialty pharmaceutical company. His past positions include Vice President of Finance at Cepheid (acquired by Danaher), as well as at Synopsys and Cisco Systems. Mr. Kitchener received his undergraduate degree in Mathematics from the University of California, Santa Cruz and earned his MBA from Cornell University.
Dushyant Pathak, PhD
Senior Vice President, Business Development
Dr. Pathak has over 15 years of senior management experience with Fortune-500, publicly traded, early-stage and start-up companies. Most recently, he was at UC Davis as its associate vice chancellor of research, innovation and technology commercialization, and executive director of Venture Catalyst. Prior to this, he was the first entrepreneur-in-residence at Mission Bay Capital, and previously worked in venture capital with Connecticut Innovations. His biotechnology executive leadership roles have included vice president of business development at iPierian; and vice president of program management and corporate development at Renovis, where he led business development, clinically-directed program management, and commercial planning. Dushyant was president, chief executive officer and a board director of Cellexicon, and CEO and board director of BioProtocol; cancer molecular-diagnostics and life science information services startups, respectively. His business development experience has included positions at Chiron Corporation, Arris, Axys Pharmaceuticals and VentureEdge LLC. Dushyant received a Ph.D. in biochemistry, molecular biology and cell biology from Northwestern University, an M.B.A. from the Haas School of Business at UC Berkeley, and a B.A. in natural science and mathematics from Bennington College. He was a postdoctoral fellow and a member of the research faculty at Yale University.
Senior Vice President, Operations
Hayley Lewis serves as our Senior Vice President of Operations, where she oversees the functional areas of Nonclinical, R&D, Analytical Development and QC, Operations and Engineering, Manufacturing, and Regulatory Affairs, and continues to be responsible for overseeing all regulatory interactions with the FDA and other government agencies. Hayley joined the company as the Vice President of Regulatory Affairs and Quality in October 2015. Prior to joining Zosano, Hayley spent over 11 years in Regulatory Affairs at Depomed, Inc., a specialty pharmaceutical company, where she was involved in the approval of 3 commercial products. Over the course of her career, she has enabled 8 investigational products to be studied in humans, 5 of which have advanced to completion of Phase 3 trials. Hayley’s pharmaceutical development experience, spanning over 20 years, covers solid oral dosage forms, and combination products such as systemic and local inhalation products, a single entity combination injectable, and transdermal systems. Ms. Lewis received a B.S. in Pharmaceutical Sciences from the University of Greenwich in England, and has attained several management diplomas from Kellogg School of Management, as well as Stanford’s Graduate School of Business.
Donald Kellerman, PharmD
Vice President, Clinical Development and Medical Affairs
Dr. Kellerman has served as our Vice President of Clinical Operations since July 2015. Prior to joining Zosano, Dr. Kellerman served as Senior Vice President of Clinical Development & Regulatory Affairs at Tonix Pharmaceuticals. Previously, Dr. Kellerman served as Senior Vice President of Clinical Development & Medical Affairs at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.) for five years. Dr. Kellerman also held the position of Senior Vice President of Development at Inspire Pharmaceuticals, Inc. for nine years, where he was responsible for all aspects of drug development, including clinical research, regulatory affairs, project management and biostatistics. He also led groups responsible for running several clinical programs in the respiratory, ophthalmology and cardiovascular areas. In addition, Dr. Kellerman has served in various clinical and project leadership positions at Glaxo Wellcome, Sepracor, Inc., and E.R. Squibb and Sons, Inc. He has more than 25 years of experience in the development of prescription pharmaceuticals and has lead- or co-authored more than 80 publications. Dr. Kellerman holds Doctor of Pharmacy and Bachelor of Science degrees from the College of Pharmacy at the University of Minnesota.